{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/A4001015","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00634959","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Randomized","arm_groups":[{"arm_group_label":"1","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"2","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"3","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"4","arm_group_description":"","arm_type":"Experimental"},{"arm_group_label":"5","arm_group_description":"","arm_type":"Placebo Comparator"}],"assignment":"Parallel Assignment","brief_summary":"To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 18:06:48","criteria":"Inclusion Criteria: - Asymptomatic HIV-1 infected male and female patients - Weight between 50 and 100kg and within the permitted range for their height - Patients with virus that targets CCR5 receptor Exclusion Criteria: - Patients with a CD4 count <250 cells/mm3 or HIV viral load <5000 copies/mL - Patients whose HIV infection has been diagnosed less than 3 months prior to screening, or for who there is evidence of recent seroconversion - Patients with acquired immunodeficiency syndrome (AIDS) or a previous AIDS diagnosis - Patients who are taking or have taken antiretroviral drugs in the eight weeks prior to the study screening visit","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 2","display_phase_internal":"PHASE_2","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"37","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"e3e4faa9-a6c4-5504-adbb-c5e85a3532f4","internal":{"content":null,"contentDigest":"989d1a622089469334f3636d726c25e0","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Asymptomatic HIV-1 infected male and female patients - Weight between 50 and 100kg and within the permitted range for their height - Patients with virus that targets CCR5 receptor Exclusion Criteria: - Patients with a CD4 count <250 cells/mm3 or HIV viral load <5000 copies/mL - Patients whose HIV infection has been diagnosed less than 3 months prior to screening, or for who there is evidence of recent seroconversion - Patients with acquired immunodeficiency syndrome (AIDS) or a previous AIDS diagnosis - Patients who are taking or have taken antiretroviral drugs in the eight weeks prior to the study screening visit","interventions":[{"arm_group_label":"1","intervention_description":"150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)","intervention_name":"Maraviroc (UK-427,857)","intervention_type":"Drug"},{"arm_group_label":"2","intervention_description":"100 mg oral tablet once daily while fasted on Days 1-10","intervention_name":"Maraviroc (UK-427,857)","intervention_type":"Drug"},{"arm_group_label":"3","intervention_description":"300 mg oral tablet once daily while fasted on Days 1-10","intervention_name":"Maraviroc (UK-427,857)","intervention_type":"Drug"},{"arm_group_label":"4","intervention_description":"150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)","intervention_name":"Maraviroc (UK-427,857)","intervention_type":"Drug"},{"arm_group_label":"5","intervention_description":"Matching placebo oral tablet on Days 1-10 (fed and fasted)","intervention_name":"Placebo","intervention_type":"Other"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":[],"last_follow_up_date":"12/01/2003 00:00:00","links":[{"description":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001015&StudyName=Effects%20Of%20Food%20And%20Dose%20Regimen%20On%20The%20Antiviral%20Effects%20Of%20Maraviroc%20%28UK-427%2C857%29%20In%20Patients%20With%20Human%20Immunodeficiency%20Virus"},{"description":"Link to ClinicalStudyResults.org","url":"http://www.clinicalstudyresults.org/drugdetails/?study_name=A4001015&sort=c.company_name&page=1&drug_id=3483"}],"locations":[{"City":"Boston","Latitude":"42.3476181","CountryDisplay":"United States","Longitude":"-71.1002881","Name":"Pfizer Investigational Site","StateDisplay":"MA","PostalCode":"02215","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Birmingham","Latitude":"33.5075555","CountryDisplay":"United States","Longitude":"-86.8093239","Name":"Pfizer Investigational Site","StateDisplay":"AL","PostalCode":"35294-2050","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.4843083","CountryDisplay":"United Kingdom","Longitude":"-0.1816441","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"SW10 9NH","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"LONDON","Latitude":"51.5532242","CountryDisplay":"United Kingdom","Longitude":"-0.1653236","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"NW3 2QG","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"KOELN","Latitude":"50.9302584","CountryDisplay":"Germany","Longitude":"6.9188847","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"50931","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"HAMBURG","Latitude":"53.5580847","CountryDisplay":"Germany","Longitude":"10.0119789","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"20099","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"FRANKFURT","Latitude":"50.0990675","CountryDisplay":"Germany","Longitude":"8.6738622","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"60596","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Double Blind","maximum_age_raw":"55 Years","maximum_age":"55","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"10/01/2018 22:48:39","number_of_arms":"5","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"An Investigation Into The Effects Of Food And Dose Regimen On Viral Load Response In HIV Infected Patients On Short-Term Monotherapy With UK-427,857 (Maraviroc)","org_study_id":"A4001015","overall_contact":{"email":null,"last_name":"Pfizer CT.gov Call Center","phone":"1-800-718-1021"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 2","primary_compl_date":null,"primary_outcomes":[{"outcome_description":"","outcome_measure":"Change from baseline in viral load","outcome_time_frame":"Day 11","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"UK-427,857 pharmacokinetics","outcome_time_frame":"Days 1-11","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Physical examination","outcome_time_frame":"Days 1, 11, 40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"12-lead ECG","outcome_time_frame":"Days 1-11 and Day 40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Relationship of change in viral load (baseline to Day 11) versus mean receptor saturation (Day 10)","outcome_time_frame":"Days 1-11","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time course of viral load from baseline to follow-up","outcome_time_frame":"Days 1-13 and Days 15, 19, 22, 25, 40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"CCR5 receptor saturation","outcome_time_frame":"Days 1, 5, 10, 11, 13, 15, 19, 40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Adverse events","outcome_time_frame":"Days 1-40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Relationship of change in viral load (baseline to Day 11) versus baseline susceptibility (IC50 and IC90)","outcome_time_frame":"Days 1-11","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Laboratory safety","outcome_time_frame":"Days 1, 3, 7, 11, 15, 40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Relationship of change in viral load (baseline to Day 11) versus average and trough plasma concentrations (Day 10)","outcome_time_frame":"Days 1-11","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Supine/standing blood pressure and pulse rate","outcome_time_frame":"Days 1-11 and Day 40","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to rebound of viral load","outcome_time_frame":"Days 1-13 and Days 15, 19, 22, 25, 40","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["Pfizer"]},"start_date":"07/01/2003 00:00:00","study_type":"Interventional","therapeutic_area":"","citations":[],"is_section_801":true}},"pageContext":{"studyId":"A4001015"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}